Drug–drug interactions in patients receiving hematopoietic stem cell transplantation

References

• Robinson SP, Boumendil A, Finel H et al. High-dose therapy with BEAC conditioning compared to BEAM conditioning prior to autologous stem cell transplantation for non-Hodgkin lymphoma: no differences in toxicity or outcome. A matched-control study of the EBMT-Lymphoma Working Party. Bone Marrow Transplant. 2018 Jun 8. doi: 10.1038/s41409-018-0196-3. [Epub ahead of print]
   Google Scholar
• Copelan EA Hematopoietic stem-cell transplantation. N Engl J Med 2006; 354(17):1813–1826.
   Google Scholar
• Valverde IA, Da Silva MJ, Retto MP Association between potential drug interactions and clinical outcomes in hematopoietic stem cell transplantations. J Oncol Pharm Pract. 2018 Jan 1.
   Google Scholar
• Copelan EA, Biggs JC, Thompson JM, et al.Treatment for acute myelocytic leukemia with allogeneic bone marrow transplantation following preparation with BU-CY2. Blood 1991; 78: 838–843.
   Google Scholar
• Lucarelli G, Giardini C, Baronciani D Bone marrow transplantation in thalassemia. Semin Hematol 1995; 32: 297–303.
   Google Scholar
• Poonkuzhali B, Chandy M, Srivastava A, et al.Glutathione S-transferase activity influences busulfan pharmacokinetics in patients with beta-thalassemia major undergoing bone marrow transplantation. Drug Metab Dispos 2001; 29(3): 264–267.
   Google Scholar
• El-Serafi I, Terelius Y, Abedi-Valugerdi M, et al.Flavin-containing monooxygenase 3 (FMO3) role in busulphan metabolic pathway. PLoS One 2017; 12(11): e0187294.
   Google Scholar
• Buggia I, Zecca M, Alessandrino EP, et al.Itraconazole can increase systemic exposure to busulfan in patients given bone marrow transplantation. GITMO (Gruppo Italiano Trapianto di Midollo Osseo). Anticancer Res 1996; 16(4A): 2083–2088.
   Google Scholar
• Hassan M, Oberg G, Björkholm M, et al.Influence of prophylactic anticonvulsant therapy on high-dose busulphan kinetics. Cancer Chemother Pharmacol 1993; 33(3): 181–186.
   Google Scholar
• Chung H, Yu KS, Hong KT, et al.A significant influence of metronidazole on busulfan pharmacokinetics: a case report of therapeutic drug monitoring. Ther Drug Monit 2017; 39(3): 208–210.
   Google Scholar
• Nilsson C, Aschan J, Hentschke P, et al.The effect of metronidazole on busulfan pharmacokinetics in patients undergoing hematopoietic stem cell transplantation. Bone Marrow Transplant 2003; 31(6): 429–435.
   Google Scholar
• Gulbis AM, Culotta KS, Jones RB, et al. Busulfan and metronidazole: an often forgotten but significant drug interaction. Ann Pharmacother 2011; 45(7–8): e39.
   Google Scholar
• Bonin M, Pursche S, Bergeman T, et al.F-ara-A pharmacokinetics during reduced-intensity conditioning therapy with fludarabine and busulfan. Bone Marrow Transplant 2007; 39(4): 201–206.
   Google Scholar
• de Castro FA, Lanchote VL, Voltarelli JC, et al.Influence of fludarabine on the pharmacokinetics of oral busulfan during pretransplant conditioning for hematopoietic stem cell transplantation. J Clin Pharmacol 2013; 53(11): 1205–1211.
   Google Scholar
• Bouligand J, Boland I, Valteau-Couanet D, et al.In children and adolescents, the pharmacodynamics of high-dose busulfan is dependent on the second alkylating agent used in the combined regimen(melphalan or thiotepa). Bone Marrow Transplant 2003; 32(10): 979–986.
   Google Scholar
• Ren S, Kalhorn TF, McDonald GB, et al.Pharmacokinetics of cyclophosphamide and its metabolites in bone marrow transplantation patients. Clin Pharmacol Ther 1998; 64: 289–301.
   Google Scholar
• Marr KA, Leisenring W, Crippa F, et al.Cyclophosphamide metabolism is affected by azole antifungals. Blood 2004; 103(4): 1557–1559.
   Google Scholar
• McDonald GB, Slattery JT, Bouvier ME, et al.Cyclophosphamide metabolism, liver toxicity, and mortality following hematopoietic stem cell transplantation. Blood 2003; 101: 2043–2048.
   Google Scholar
• Nagamura F, Takahashi T, Takeuchi M, et al.Effect of cyclophosphamide on serum cyclosporine levels at the conditioning of hematopoietic stem cell transplantation. Bone Marrow Transplant 2003; 32(11): 1051–1058.
   Google Scholar
• Chen TL, Passos-Coelho JL, Noe DA, et al.Nonlinear pharmacokinetics of cyclophosphamide in patients with metastatic breast cancer receiving high-dose chemotherapy followed by autologous bone marrow transplantation. Cancer Res 1995; 55(4): 810–816.
   Google Scholar
• Gryn J, Gordon R, Bapat A, et al.Pentostatin increases the acute toxicity of high dose cyclophosphamide. Bone Marrow Transplant 1993; 12(3): 217–220.
   Google Scholar
• Zhuo X, Zheng N, Felix CA, et al. Kinetics and regulation of cytochrome P450-mediated etoposide metabolism. Drug Metab Dispos 2004; 32(9): 993–1000.
   Google Scholar
• Rodman JH, Murry DJ, Madden T, et al. Altered etoposide pharmacokinetics and time to engraftment in pediatric patients undergoing autologous bone marrow transplantation. J Clin Oncol 1994; 12(11): 2390–2397.
   Google Scholar
• Mross K, Bewermeier P, Krüger W, et al.Pharmacokinetics of undiluted or diluted high-dose etoposide with or without busulfan administered to patients with hematologic malignancies. J Clin Oncol 1994; 12(7): 1468–1474.
   Google Scholar
• El Fakih R, Obi GA, Scholoff A, et al. Systemic effects of oral budesonide in hematopoietic transplant: implications of drug interaction with azoles. Bone Marrow Transplant 2012; 47(10): 1370–1371.
   Google Scholar
• Boogaerts MA, Zachee P, Verwilghen RL Cyclosporin, methylprednisolone, and convulsions. Lancet Lond Engl 1982; 2(8309): 1216–1217.
   Google Scholar
• Durrant S, Chipping PM, Palmer S, et al., methylprednisolone, and convulsions. Lancet 1982; 320(8302): 829–830.
   Google Scholar
• Poon A, Ly LK Common potential drug interactions following hematopoietic cell transplantation. In: Forman SJ, Negrin RS, Antin JH, et al., editors. Thomas’ hematopoietic cell transplantation. John Wiley & Sons, Ltd: Chichester, UK, 2016: 1206–1217.
   Google Scholar
• Osowski CL, Dix SP, Lin LS, et al.Evaluation of the drug interaction between intravenous high-dose fluconazole and cyclosporine or tacrolimus in bone marrow transplant patients. Transplantation 1996; 61(8): 1268–1272.
   Google Scholar
• Mihara A, Mori T, Aisa Y et al. Greater impact of oral fluconazole on drug interaction with intravenous calcineurin inhibitors as compared with intravenous fluconazole. Eur J Clin Pharmacol. 2008; 64(1): 89–91.
   Google Scholar
• Mori T, Aisa Y, Kato J, et al.Drug interaction between oral solution itraconazole and calcineurin inhibitors in allogeneic hematopoietic stem cell transplantation recipients: an association with bioavailability of solution itraconazole. Int J Hematol 2009; 90(1): 103–107.
   Google Scholar
• Nara M, Takahashi N, Miura M et al. Effect of itraconazole on the concentrations of tacrolimus and cyclosporine in the blood of patients receiving allogeneic hematopoietic stem cell transplants. Eur J Clin Pharmacol. 2013; 69(6): 1321–1329.
   Google Scholar
• Leather H, Boyette RM, Tian L, et al. Pharmacokinetic evaluation of the drug interaction between intravenous itraconazole and intravenous tacrolimus or intravenous cyclosporin A in allogeneic hematopoietic stem cell transplant recipients. Biol Blood Marrow Transplant 2006; 12(3): 325–334.
   Google Scholar
• Sánchez-Ortega I, Vázquez L, Montes C et al. Effect of posaconazole on cyclosporine blood levels and dose adjustment in allogeneic blood and marrow transplant recipients. Antimicrob Agents Chemother 2012; 56(12): 6422–6424.
   Google Scholar
• Masoumi HT, Hadjibabaie M, Vaezi M, et al. Evaluation of the interaction of intravenous and oral voriconazole with oral cyclosporine in Iranian HSCT Patients. J Res Pharm Pract 2017; 6(2): 77–82.
   Google Scholar
• Kikuchi T, Mori T, Yamane A et al. Variable magnitude of drug interaction between oral voriconazole and cyclosporine A in recipients of allogeneic hematopoietic stem cell transplantation. Clin Transplant 2012; 26(5): E544–548.
   Google Scholar
• Mori T, Aisa Y, Kato J et al. Drug interaction between voriconazole and calcineurin inhibitors in allogeneic hematopoietic stem cell transplant recipients. Bone Marrow Transplant 2009; 44(6): 371–374.
   Google Scholar
• Valenzuela R, Torres JP, Salas C et al. Drug interaction of voriconazole-cyclosporine in children undergoing hematopoietic stem cell transplantation (2013–2014). Rev Chil Infectologia Organo Soc Chil Infectologia 2017; 34(1): 14–18.
   Google Scholar
• Caihong Q, Weimin L, Jieming Z Elevation of blood ciclosporin levels by voriconazole leading to leukoencephalopathy. J Pharmacol Pharmacother 2013; 4(4): 294–297.
   Google Scholar
• Groll AH, Kolve H, Ehlert K et al. Pharmacokinetic interaction between voriconazole and ciclosporin A following allogeneic bone marrow transplantation. J Antimicrob Chemother 2004; 53(1): 113–114.
   Google Scholar
• Neofytos D, Avdic E, Magiorakos AP Clinical safety and tolerability issues in use of triazole derivatives in management of fungal infections. Drug Healthc Patient Saf 2010; 2: 27–38.
   Google Scholar
• Nishimoto M, Koh H, Tokuwame A et al. Drug interactions and safety profiles with concomitant use of caspofungin and calcineurin inhibitors in allogeneic haematopoietic cell transplantation. Br J Clin Pharmacol. 2017; 83(9): 2000–2007.
   Google Scholar
• Bernard E, Goutelle S, Bertrand Y, et al. Pharmacokinetic drug-drug interaction of calcium channel blockers with cyclosporine in hematopoietic stem cell transplant children. Ann Pharmacother 2014; 48(12): 1580–1584.
   Google Scholar
• Atiq F, Broers AEC, Andrews LM et al. A clinically relevant pharmacokinetic interaction between cyclosporine and imatinib. Eur J Clin Pharmacol 2016; 72(6): 719–723.
   Google Scholar
• Bleyzac N, Kebaili K, Mialou V et al. Pharmacokinetic drug interaction between cyclosporine and imatinib in bone marrow transplant children and model-based reappraisal of imatinib drug interaction profile. Ther Drug Monit 2014; 36(6): 724–729.
   Google Scholar
• Furrer K, Schaffner A, Vavricka SR et al. Nephrotoxicity of cyclosporine A and amphotericin B-deoxycholate as continuous infusion in allogeneic stem cell transplantation. Swiss Med Wkly. 2002; 132(23–24): 316–320.
   Google Scholar
• Wood P, Yin JA Oxymetholone hepatotoxicity enhanced by concomitant use of cyclosporin A in a bone marrow transplant patient. Clin Lab Haematol 1994; 16(2): 201–204.
   Google Scholar
• Masarwa R, Shamriz O, Zilkha A et al. Bosentan-induced reduction in Cyclosporine-A Levels: a rare interaction in an infant with osteopetrosis and severe pulmonary hypertension. J Pediatr Hematol Oncol 2015; 37(7): 573–574.
   Google Scholar
• Carstensen H, Jacobsen N, Dieperink H Interaction between cyclosporin A and phenobarbitone. Br J Clin Pharmacol 1986; 21(5): 550–551.
   Google Scholar
• Zelunka EJ Intravenous cyclosporine-rifampin interaction in a pediatric bone marrow transplant recipient. Pharmacotherapy 2002; 22(3): 387–390.
   Google Scholar
• El-Asmar J, Gonzalez R, Bookout R, et al.Clotrimazole troches induce supratherapeutic blood levels of sirolimus and tacrolimus in an allogeneic hematopoietic cell-transplant recipient resulting in acute kidney injury. Hematol Oncol Stem Cell Ther 2016; 9(4): 157–161.
   Google Scholar
• Gondo H, Okamura C, Osaki K et al. Acquired Pelger-Huët anomaly in association with concomitant tacrolimus and fluconazole therapy following allogeneic bone marrow transplantation. Bone Marrow Transplant 2000; 26(11): 1255–1257.
   Google Scholar
• Nara M, Takahashi N, Miura M et al. Effect of oral itraconazole on the pharmacokinetics of tacrolimus in a hematopoietic stem cell transplant recipient with CYP3A5*3/*3. Am J Hematol. 2010; 85(8): 634–635.
   Google Scholar
• Mori T, Kato J, Yamane A, et al.Drug interaction between voriconazole and tacrolimus and its association with the bioavailability of oral voriconazole in recipients of allogeneic hematopoietic stem cell transplantation. Int J Hematol 2012; 95(5): 564–569.
   Google Scholar
• Iwamoto T, Monma F, Fujieda A et al. Effect of genetic polymorphism of CYP3A5 and CYP2C19 and concomitant use of voriconazole on blood tacrolimus concentration in patients receiving hematopoietic stem cell transplantation. Ther Drug Monit. 2015; 37(5): 581–588.
   Google Scholar
• Takashima M, Taniguchi R, Yano I et al. Pharmacokinetic interactions between calcineurin inhibitors and azole antifungals in hematopoietic stem cell transplant recipients. Iryo Yakugaku Jpn J Pharm HealthC Sci 2009; 35(4): 233–239.
   Google Scholar
• Miceli M, Cronin S, Ayash L et al. Significant interaction of tacrolimus with ritonavir during allogeneic hematopoietic SCT in an HIV-infected patient. Bone Marrow Transplant. 2012; 47(8): 1140–1142.
   Google Scholar
• Choy M Tacrolimus interaction with clotrimazole: a concise case report and literature review. Pharm Ther 2010; 35(10): 568–569.
   Google Scholar
• Watanabe N, Higashi H, Nakamura S et al. The possible clinical impact of risperidone on P-glycoprotein-mediated transport of tacrolimus: a case report and in vitro study. Biopharm Drug Dispos. 2018; 39(1): 30–37.
   Google Scholar
• Ibrahim RB, Abella EM, Chandrasekar PH Tacrolimus-clarithromycin interaction in a patient receiving bone marrow transplantation. Ann Pharmacother 2002; 36(12): 1971–1972.
   Google Scholar
• Mori T, Aisa Y, Nakazato T et al. Tacrolimus-azithromycin interaction in a recipient of allogeneic bone marrow transplantation. Transpl Int 2005; 18(6): 757–758.
   Google Scholar
• Kitazawa F, Fuchida S-I, Kado Y et al. Pharmacokinetic interaction between tacrolimus and fentanyl in patients receiving allogeneic hematopoietic stem cell transplantation. Ann Transplant 2017; 22: 575–580.
   Google Scholar
• Iwamoto T, Monma F, Fujieda A et al. Hepatic drug interaction between tacrolimus and lansoprazole in a bone marrow transplant patient receiving voriconazole and harboring CYP2C19 and CYP3A5 heterozygous mutations. Clin Ther. 2011; 33(8): 1077–1080.
   Google Scholar
• Mori T, Aisa Y, Kato J et al. Overcoming the effect of rifampin on the tacrolimus metabolism by itraconazole administration in an allogeneic hematopoietic stem cell transplant recipient. Int J Hematol. 2010; 91(3): 553–554.
   Google Scholar
• Mori T, Shimizu T, Kato J et al. Nephrotoxicity of concomitant use of tacrolimus and teicoplanin in allogeneic hematopoietic stem cell transplant recipients. Transpl Infect Dis. 2014; 16(2): 329–332.
   Google Scholar
• Shayani S, Palmer JM, Stiller T et al. Aprepitant (Emend) significantly increases sirolimus levels in patients undergoing allogeneic hematopoietic SCT. Bone Marrow Transplant. 2012; 47(2): 291–293.
   Google Scholar
• Nwaroh E, Jupp J, Jadusingh E, et al. Clinical impact and management of fluconazole discontinuation on sirolimus levels in bone marrow transplant patients. J Oncol Pharm Pract 2018; 24(3): 235–238.
   Google Scholar
• Said A, Garnick JJ, Dieterle N et al. Sirolimus-itraconazole interaction in a hematopoietic stem cell transplant recipient. Pharmacotherapy. 2006; 26(2): 289–295.
   Google Scholar
• Cho E, Chan H, Nguyen HM et al. Management of drug interaction between posaconazole and sirolimus in patients who undergo hematopoietic stem cell transplant. Pharmacotherapy. 2015; 35(6): 578–585.
   Google Scholar
• Kubiak DW, Koo S, Hammond SP et al. Safety of posaconazole and sirolimus coadministration in allogeneic hematopoietic stem cell transplants.Biol Blood Marrow Transplant. 2012; 18(9): 1462–1465.
   Google Scholar
• Marty FM, Lowry CM, Cutler CS et al. Voriconazole and sirolimus coadministration after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2006; 12(5): 552–559.
   Google Scholar
• Ceberio I, Dai K, Devlin SM et al. Safety of voriconazole and sirolimus coadministration after allogeneic hematopoietic SCT. Bone Marrow Transplant. 2015; 50(3): 438–443.
   Google Scholar
• Engle JA, Fair C Sirolimus and mirabegron interaction in a hematopoietic cell transplant patient. J Oncol Pharm Pract 2018: 24(8): 627–631.
   Google Scholar
• Wasko JA, Westholder JS, Jacobson PA Rifampin-sirolimus-voriconazole interaction in a hematopoietic cell transplant recipient. J Oncol Pharm Pract 2017; 23(1): 75–79.
   Google Scholar
• Goutelle S, Mialou V, Gouraud A et al. Probable drug interaction between intravenous ciprofloxacin and mycophenolate mofetil in a bone marrow transplant recipient: Pharmacotherapy. 2011; 31(1): 114.
   Google Scholar
• Venkatakrishnan K, von Moltke LL, Greenblatt DJ Effects of the antifungal agents on oxidative drug metabolism: clinical relevance. Clin Pharmacokinet 2000; 38: 111–180.
   Google Scholar
• Mathijssen RH, van Alphen RJ, Verweij J, et al.Clinical pharmacokinetics and metabolism of irinotecan (CPT-11). Clin Cancer Res 2001; 7(8): 2182–2194.
   Google Scholar
• Murry DJ, Cherrick I, Salama V, et al.Influence of phenytoin on the disposition of irinotecan: a case report. J Pediatr Hematol Oncol 2002; 24(2): 130–133.
   Google Scholar
• Kowalsky SF, Dixon DM Fluconazole: a new antifungal agent. Clin Pharm 1991; 10: 179–194.
   Google Scholar
• Glotzbecker B, Duncan C, Alyea E 3rd, et al. Important drug interactions in hematopoietic stem cell transplantation: what every physician should know. Biol Blood Marrow Transplant. 2012; 18(7): 989–1006.
   Google Scholar
• Bonay M, Jonville-Bera AP, Diot P et al. Possible interaction between phenobarbital, carbamazepine and itraconazole. Drug Saf 1993; 9: 309–311.
   Google Scholar
• Inoue Y, Saito T, Ogawa K, et al.Drug interactions between micafungin at high doses and cyclosporine A in febrile neutropenia patients after allogeneic hematopoietic stem cell transplantation. Int J Clin Pharmacol Ther 2012; 50(11): 831–837.
   Google Scholar
• Haouala A, Widmer N, Duchosal MA, et al.Drug interactions with the tyrosine kinase inhibitors imatinib, dasatinib, and nilotinib. Blood 2011; 117: e75–e87.
   Google Scholar
• Bril F, Gonzalez CD, Di Girolamo G Antimicrobial agents associated with Q-T interval prolongation. Curr Drug Saf 2010; 5: 85–92.
   Google Scholar
• Wen Z-P, Fan -S-S, Du C et al. Drug-drug interaction between valproic acid and meropenem: a retrospective analysis of electronic medical records from neurosurgery inpatients. J Clin Pharm Ther. 2017; 42(2): 221–227.
   Google Scholar
• Egger SS, Meier S, Leu C, et al.Drug interactions and adverse events associated with antimycotic drugs used for invasive aspergillosis in hematopoietic SCT. Bone Marrow Transplant 2010; 45(7): 1197–1203.
   Google Scholar
• Servais S, Beguin Y, Delens L, et al.Novel approaches for preventing acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Expert Opin Invest Drugs 2016; 25(8): 957–972.
   Google Scholar
• Wang L, You ZH, Chen X, et al.A computational-based method for predicting drug–target interactions by using stacked autoencoder deep neural network. J Comput Biol 2018; 25(3): 361–373.
   Google Scholar
• Chao NJ Pharmacologic Prevention of Acute Graft-versus-Host Disease. In: thomas’ Hematopoietic Cell Transplantation. Wiley-Blackwell, New York. 2016: 990–1006.
   Google Scholar
• Tirkkonen T, Heikkila P, Huupponen R, et al.Potential CYP2C9-mediated drug-drug interactions in hospitalized type 2 diabetes mellitus patients treated with the sulphonylureas glibenclamide, glimepiride or glipizide. J Intern Med 2010; 268: 359–366.
   Google Scholar
• Miura M, Takahashi N, Kanno S, et al.Drug interaction of (S)-warfarin, and not (R)-warfarin, with itraconazole in a hematopoietic stem cell transplant recipient. Clin Chim Acta 2011; 412(21–22): 2002–2006.
   Google Scholar
• Gholaminezhad S, Hadjibabaie M, Gholami K, et al.Pattern and associated factors of potential drug-drug interactions in both pre- and early post-hematopoietic stem cell transplantation stages at a referral center in the Middle East. Ann Hematol 2014; 93(11): 1913–1922.
   Google Scholar